RA0449

antibody from Oursmab

Targeting: KLRC1 CD159a, NKG2, NKG2-A, NKG2-B

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0449

Provider

Oursmab

Product name

Monalizumab (Biosimilar Reference Antibody) (KLRC1)

Antibody type

Monoclonal

Description

Monalizumab (also known as IPH-2201) is an investigational, humanized IgG4 monoclonal antibody that targets the immune checkpoint receptor NKG2A (CD159a). NKG2A forms a heterodimer with CD94 and is expressed on natural killer (NK) cells and a subset of CD8+ T cells. It binds to the non-classical MHC class I molecule HLA-E, which is often upregulated on tumor cells and infected cells. By blocking the interaction between NKG2A and HLA-E, monalizumab releases the inhibitory signal on NK cells and T cells, thereby enhancing their cytotoxic activity against tumors. It is being developed as an immune checkpoint inhibitor for the treatment of advanced solid tumors and hematologic malignancies, often in combination with other therapies (e.g., anti-PD-L1 antibodies).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.